"FDA approval for TruSight Oncology Comprehensive with accompanying companion diagnostics marks an awaited milestone for our oncology customers and community," said Everett Cunningham, chief commercial officer of Illumina. "We are committed to partnering with industry leaders like Bayer and Lilly to advance cancer diagnostics and help broaden access to precision oncology for more patients."A CDx test may identify whether a patient's tumor has a specific gene change or biomarker that can be targeted by a the ...

Investors in Illumina, Inc. (ILMN) need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 20, 2024 $75 Call had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean ...

da-kukIntroduction Illumina (NASDAQ:ILMN) has finally rid itself of GRAIL. My last look at the stock followed its 2023 financial report, wherein revenues and gross margins dropped and SG&A expenses climbed. The company also projected "approximately flat" revenues in 2024. This was in the context of a valuation that was rich. My recommendation was "sell," noting that the company's "premium valuation is not justified by its current performance or future prospects." Illumina stock is -1.68% since this upda ...

blackred Illumina, Inc. (NASDAQ:ILMN), the life sciences and tool company, is a company I’ve had my eye on for quite some time. I’ve never invested in this company before, and now might be the time to start a position. In this article, I will outline why I think it looks bullish. I will use technical analysis tools such as price action, volume, momentum, and relative strength to explain my reasoning. Chart 1 – ILMN Weekly with 30- Week Moving Average, Momentum, Volume, and Relative Strength StockCharts. ...

Illumina, Inc. (NASDAQ:ILMN) Illumina 2024 Strategy Update Special Call August 13, 2024 11:00 AM ET Company Participants Salli Schwartz - Head of IR Jacob Thaysen - CEO Steve Barnard - CTO Ankur Dhingra - CFO Conference Call Participants Operator Salli Schwartz Thank you for joining us today. My name is Salli Schwartz and I'm Illumina's Head of Investor Relations. Before we get started, I need to provide a few cautionary notes. This event is being recorded and will be archived in the Investors section of ou ...

-- Company poised to accelerate revenue growth into high single digits over next three years, enabled by core genomics portfolio -- Innovations to enable development of transformative applications using multiomics-- Illumina to offer higher quality insights to customers, helping them improve the overall end-to-end workflow experience and lower cost-- Delivering double digit to teens non-GAAP diluted earnings per share growth 2025-2027-- Illumina and the Broad Institute of MIT and Harvard announce new resear ...

Did you analyze how Illumina (ILMN) fared in its international operations for the quarter ending June 2024? Given the widespread global presence of this genetic testing tools company, scrutinizing the trends in international revenues becomes imperative to assess its financial strength and future growth possibilities.In the current era of a tightly interconnected global economy, the proficiency of a company to penetrate international markets significantly influences its financial health and trajectory of gro ...

Illumina Inc. (ILMN) reported second-quarter 2024 adjusted earnings per share (EPS) of 36 cents, which beat the Zacks Consensus Estimate of 12 cents by a stupendous 200%. The bottom line was above the year-ago quarter’s figure of 32 cents.The adjustments exclude the impact of GRAIL’s pre-acquisition net operating losses on GILTI, the utilization of U.S. foreign tax credits and the Pillar Two global minimum top-up tax, which became effective from the first quarter of 2024, among others.Including one-time ite ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2024 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-35406 Illumina, Inc. (Exact name of registrant as specified in its charter) Delaware 33-0804655 (State or other jurisdiction of incorporation o ...

Illumina, Inc. (NASDAQ:ILMN) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Salli Schwartz - Vice President of Investor Relations Jacob Thaysen - Chief Executive Officer Ankur Dhingra - Chief Financial Officer Conference Call Participants Vijay Kumar - Evercore ISI Conor McNamara - RBC Capital Markets Patrick Donnelly - Citi Doug Schenkel - Wolfe Research Dan Arias - Stifel Tycho Peterson - Jefferies Subha Nambi - Guggenheim Securities Puneet Souda - Leerink Partners Sung Ji ...